Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer

PD-1/PD-L1 blockade therapies have displayed extraordinary clinical efficacy for melanoma, renal, bladder and lung cancer; however, only a minority of colorectal cancer (CRC) patients benefit from these treatments. The efficacy of PD-1/PD-L1 blockade in CRC is limited by the complexities of tumor mi...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cancer 2024-11, Vol.23 (1), p.252-37, Article 252
Main Authors: Xie, Qi, Liu, Xiaolin, Liu, Rengyun, Pan, Jingxuan, Liang, Jing
Format: Article
Language:English
Subjects:
Animals
B cells
B7-H1 Antigen - antagonists & inhibitors
Cancer
Care and treatment
Cellular mechanism
Colorectal cancer
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - immunology
Colorectal Neoplasms - therapy
Combinational therapy
Development and progression
Humans
Immune Checkpoint Inhibitors - pharmacology
Immune Checkpoint Inhibitors - therapeutic use
Immune response
Immunity, Innate
Immunotherapy
Immunotherapy - methods
Innate immunity
Lung cancer
PD-1/PD-L1 blockade
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Review
T cells
Tumor Microenvironment - immunology
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PD-1/PD-L1 blockade therapies have displayed extraordinary clinical efficacy for melanoma, renal, bladder and lung cancer; however, only a minority of colorectal cancer (CRC) patients benefit from these treatments. The efficacy of PD-1/PD-L1 blockade in CRC is limited by the complexities of tumor microenvironment. PD-1/PD-L1 blockade immunotherapy is based on T cell-centered view of tumor immunity. However, the onset and maintenance of T cell responses and the development of long-lasting memory T cells depend on innate immune responses. Acknowledging the pivotal role of innate immunity in anti-tumor immune response, this review encapsulates the employment of combinational therapies those involve PD-1/PD-L1 blockade alongside the activation of innate immunity and explores the underlying cellular mechanisms, aiming to harnessing innate immune responses to induce long-lasting tumor control for CRC patients who received PD-1/PD-L1 blockade therapy.
ISSN:1476-4598
1476-4598
DOI:10.1186/s12943-024-02166-w